{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Patient headache and vomiting worsened by April 2022.",
        "timestamp": "2022-04",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Headache and vomiting worsened",
              "progression": "gradual",
              "onset": "April 2022",
              "associated_symptoms": [
                "Headache",
                "Vomiting"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Repeat chest CT showed no changes compared to the previous scan.",
        "timestamp": "2022-04",
        "clinical_data": {}
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Diagnosis of lung adenocarcinoma with leptomeningeal metastasis (LM) confirmed. Patient classified as having stage CT3NxM1a lung cancer according to the Eighth Edition of the TNM Classification for Lung Cancer.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34",
              "label": "Malignant neoplasm of bronchus and lung",
              "status": "active"
            },
            {
              "code": "C79.31",
              "label": "Secondary malignant neoplasm of brain",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Lumbar puncture performed with CSF pressure >330 mmH2O. 30 mL CSF released. Intrathecal chemotherapy (ITC) administered, consisting of dexamethasone 5 mg with pemetrexed 50 mg (day 1, day 10).",
        "timestamp": "2022-04-24",
        "clinical_data": {
          "procedures": [
            {
              "name": "Lumbar puncture",
              "date": null,
              "outcome": null
            }
          ],
          "labs": [
            {
              "test": "Cerebrospinal Fluid Pressure",
              "value": ">330",
              "unit": "mmH2O",
              "timestamp": null
            }
          ],
          "medications": [
            {
              "drug": "dexamethasone",
              "dosage": "5 mg",
              "frequency": "day 1, day 10",
              "modality": "intrathecal",
              "start_date": null,
              "end_date": null,
              "indication": "chemotherapy"
            },
            {
              "drug": "pemetrexed",
              "dosage": "50 mg",
              "frequency": "day 1, day 10",
              "modality": "intrathecal",
              "start_date": null,
              "end_date": null,
              "indication": "chemotherapy"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Headache and vomiting symptoms improved significantly. CSF cytology negative for malignant cells.",
        "timestamp": "2022-04",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Headache and vomiting symptoms improved significantly."
            }
          ],
          "labs": [
            {
              "test": "CSF cytology",
              "value": "negative",
              "finding": "malignant cells"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Systemic therapy: pemetrexed with bevacizumab as first-line treatment and maintenance therapy. Efficacy evaluated as stable disease.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0974134",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1236804",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "stable disease",
              "status": null,
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Headache and vomiting worsened by the end of cycle 6 of systemic therapy.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Headache and vomiting worsened",
              "progression": "worsening",
              "exacerbating_factors": [
                "systemic therapy"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "ITC regimen administered multiple times. Cephalic symptoms and lung lesions remained stable. Cranial MRI showed no clear manifestations of brain parenchymal or meningeal metastases. CSF analysis revealed no malignant tumor cells.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Cranial MRI",
              "body_part": "Brain",
              "modality": "MRI",
              "finding": "no clear manifestations of brain parenchymal or meningeal metastases"
            }
          ],
          "labs": [
            {
              "test": "CSF analysis",
              "value": "no malignant tumor cells"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Patient presented with worsening headache, vomiting, and transient loss of consciousness.",
        "timestamp": "2022-10",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Patient presented with worsening headache, vomiting, and transient loss of consciousness.",
              "associated_symptoms": [
                "C0018681",
                "C0042963",
                "C0239693"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "ITC regimen switched to gemcitabine (20 mg, 1/week) due to poor response to pemetrexed, resulting in relief of headache and vomiting symptoms.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0016621",
              "dosage": "20 mg",
              "frequency": "1/week",
              "modality": "IV",
              "indication": "Poor response to pemetrexed"
            },
            {
              "drug": "C0978743",
              "indication": "Headache",
              "end_date": "Unknown"
            },
            {
              "drug": "C0978743",
              "indication": "Vomiting",
              "end_date": "Unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "Second-line systemic therapy: intravenous PD-1 inhibitor tislelizumab (200 mg, 1/21 days) combined with oral anlotinib (8 mg, 1/day). Anlotinib discontinued after one cycle due to uncontrolled hypertension.",
        "clinical_data": {
          "medications": [
            {
              "drug": "tislelizumab",
              "dosage": "200 mg",
              "frequency": "1/21 days",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "anlotinib",
              "dosage": "8 mg",
              "frequency": "1/day",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "uncontrolled hypertension",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "CSF genetic testing using second-generation sequencing technology revealed BRAF N581I missense mutation (abundance 13.93%) and CDKN2A mutation (abundance 39.21%).",
        "clinical_data": {
          "labs": [
            {
              "test": "Genetic testing",
              "value": "BRAF N581I missense mutation (abundance 13.93%) and CDKN2A mutation (abundance 39.21%)",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N13",
      "label": "Step 13",
      "customData": {
        "node_id": "M",
        "node_step_index": 12,
        "content": "Started on oral mitogen-activated extracellular signal-regulated kinase inhibitor trametinib (2 mg, once daily) as third-line systemic therapy. ITC using gemcitabine at a dose of 20 mg every 1\u20132 weeks was continued.",
        "timestamp": "2022-11-16",
        "clinical_data": {
          "medications": [
            {
              "drug": "trametinib",
              "dosage": "2 mg",
              "frequency": "once daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "gemcitabine",
              "dosage": "20 mg",
              "frequency": "every 1\u20132 weeks",
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N14",
      "label": "Step 14",
      "customData": {
        "node_id": "N",
        "node_step_index": 1,
        "clinical_data": {}
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Chest CT performed to assess the patient's condition."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Diagnostic workup and imaging review leading to diagnosis."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Treatment initiated for lung adenocarcinoma with leptomeningeal metastasis."
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Response to initial intrathecal chemotherapy."
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Initiation of systemic therapy and evaluation of efficacy."
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Worsening of symptoms despite systemic therapy."
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Continued intrathecal chemotherapy and monitoring of disease status."
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Clinical deterioration with new symptoms."
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "Change in intrathecal chemotherapy regimen due to poor response to initial treatment."
      }
    },
    {
      "from": "N10",
      "to": "N11",
      "data": {
        "edge_id": "J_to_K",
        "branch_flag": true,
        "content": "Initiation of second-line systemic therapy."
      }
    },
    {
      "from": "N11",
      "to": "N12",
      "data": {
        "edge_id": "K_to_L",
        "branch_flag": true,
        "content": "Genetic testing performed to identify potential therapeutic targets."
      }
    },
    {
      "from": "N12",
      "to": "N13",
      "data": {
        "edge_id": "L_to_M",
        "branch_flag": true,
        "content": "Initiation of third-line systemic therapy based on genetic testing results."
      }
    },
    {
      "from": "N13",
      "to": "N14",
      "data": {
        "edge_id": "M_to_N",
        "branch_flag": true,
        "content": "Further disease progression and treatment changes."
      }
    }
  ]
}